Foreign drugs continue to disappear from Russian pharmaceutical retail

1 September 2020

Foreign drugs continue to disappear from the Russian pharmaceutical retail, posing a threat of a shortage of medicines that could be recommended for the treatment of some serious diseases, according to recent studies prepared by some local market research agencies and pharmaceutical business analysts, reports The Pharma Letter’s local correspondent.

Following Roche (ROG: SIX), which has recently suspended supplies of its Madopar (levodopa and benzerazide), which is used to treat Parkinson's disease), as well as Roaccutane (isotretinoin), a drug, intended for the treatment of severe forms of acne) to Russia, the local range has been recently reduced by one of its major global rivals – Sanofi(Euronext: SAN), as the company earlier this year stopped exports of its Lasix (furosemide) diuretic drug to the Russian market.

This has already caused serious concerns for the Russian government, particularly the local Ministry of Health, which fears that the shortage of this drug may pose a threat to Russia’s state security in the pharmaceutical field.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Pharmaceutical